Current Cardiovascular Risk Reports

, Volume 4, Issue 4, pp 311–317

Unanswered Questions Regarding the Effect of Androgen Deprivation Therapy for Prostate Cancer on Cardiovascular Disease Risk in Black Men

Article

DOI: 10.1007/s12170-010-0110-z

Cite this article as:
Winkfield, K.M. & Albert, M.A. Curr Cardio Risk Rep (2010) 4: 311. doi:10.1007/s12170-010-0110-z

Abstract

Prostate cancer is the most common visceral malignancy affecting men in the United States. Patient tailored therapy is based on risk group categories. In recent years, androgen deprivation therapy has played a greater role in the treatment of prostate cancer. However, androgen suppression can lead to changes in the metabolic profile that increase the risk of cardiovascular disease in men. Evidence is emerging that hormonal therapy increases the risk of cardiac morbidity and mortality. This finding is of particular concern for black men. Compared with other racial and ethnic groups, black men in the United States have the highest prevalence of both prostate cancer and cardiovascular mortality. Due to increased utilization of hormone therapy in the treatment of prostate cancer, and high prevalence of prostate cancer in blacks, the risk of cardiac disease following androgen deprivation therapy in black men needs to be determined.

Keywords

Androgen deprivation therapy Prostate cancer treatment Cardiovascular risk factors Health disparities Cardiovascular mortality 

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Harvard Radiation Oncology Program, Harvard Medical School, Department of Radiation OncologyMassachusetts General HospitalBostonUSA
  2. 2.Harvard Medical School, Divisions of Cardiology and Preventive MedicineBrigham & Women’s HospitalBostonUSA

Personalised recommendations